Comparison of effects of Dapagliflozin and Alogliptin in treatment of patients with type 2 diabetes
Objective:To compare effects of Dapagliflozin and Alogliptin in treatment of patients with type 2 diabetes.Methods:The clinical data of 100 patients with type 2 diabetes admitted to the hospital from November 2018 to December 2022 were retrospectively analyzed.According to different treatment options,they were divided into control group(47 cases)and observation group(53 cases).The control group was treated with Alogliptin,while the observation group was treated with Dapagliflozin.The levels of glucose metabolism indicators[fasting blood glucose(FPG),2h postprandial blood glucose(2hPG),glycosylated hemoglobin(HbA1c)],islet function indicators[fasting insulin(FINS),insulin resistance indicator(HOMA-IR),islet β cell secretory function indicator(HOMA-β)]and inflammatory indicators[interleukin-6(IL-6),cystatin C(CysC),C-reactive protein(CRP)]before and after the treatment,and the incidence of adverse reactions during treatment were compared between the two groups.Results:After the treatment,the levels of FPG,HbA1c,2hPG and HOMA-IR in the two groups were lower than those before the treatment,and the levels of HOMA-β and FINS were higher than those before the treatment,but there were no significant differences between the two groups(P>0.05).After the treatment,the levels of IL-6,CysC and CRP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Dapagliflozin and Alogliptin can reduce the levels of glucose metabolism indicators and improve the levels of islet function indicators in the patients with type 2 diabetes,but Dapagliflozin can reduce the levels of inflammatory indicators.It is superior to Alogliptin.
Type 2 diabetesAlogliptinDapagliflozinGlucose metabolismIslet functionInflammatory indicatorAdverse reaction
万方数据
维普
